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REPLY
We agree with Dr. Davila that the pathogenesis and medical
treatment of chronic Chagas’ disease is complex and warrants
further research. In our study, which included only a small number
of patients with Chagas’ disease, there was no significant difference
in sympathetic activation between Chagas and non-Chagas etiol-
ogies of heart failure (Fig. 2A of reference 1). This finding is in
agreement with some (2,3), but not all (4) prior investigations. Of
note, uniquely in our study, efferent muscle sympathetic nerve
activity was measured directly utilizing microneurography, a sensi-
tive and reproducible technique, rather than indirectly with plasma
norepinephrine levels. Studies of the sympathetic activation in
Chagas’ disease, which include patients with and without overt
systolic dysfunction, may be able to distinguish between sympa-
thetic dysregulation attributable to T. cruzi infiltration of cardiac
nerves/autonomic ganglia and that attributable to the cardiac
dysfunction present late in Chagas’ disease.
Although many hypotheses have been advanced to explain the
sympathetic activation in heart failure, including baroreceptor
dysfunction, overactivity of the arterial and/or muscle chemore-
ceptors, or abnormalities in the “heart failure milicu,” the exact
mechanisms have not been established. It remains unknown
whether the same mechanisms underlie the sympathetic activation
in Chagas’ heart disease. Finally, the findings in our study lend
support to the concept that, regardless of the etiology of left
ventricular dysfunction and heart failure, a chronic exercise regi-
men is sympatholytic and beneficial. Studies enrolling larger
numbers of patients with Chagas’ heart disease are underway in our
laboratory in the hope of answering this question definitively.
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Assessment of Diastolic Function
Using Myocardial Velocity Gradient
I read with interest an editorial comment by Dr. Shah (1)
regarding a study on myocardial velocity gradient (MVG) and left
ventricular dysfunction (2). I agree with his comment that no
noninvasive measure of “pure” diastolic function has yet been
achieved.
In his comment, Dr. Shah stated that diastolic MVG measure-
ment was first reported by Fleming et al. (3) as being somewhat
insensitive to preload or atrial filling pressures. To my knowledge,
however, in 1994, MVG was introduced merely for the evaluation
of myocardial contractility. Fleming et al. compared the velocity
gradient with wall-thickness change to validate the new method-
ology (3). The application of MVG to assess diastolic dysfunction
had to wait until the report by Palka et al. (4) differentiating
hypertrophic cardiomyopathy from athletes’ hearts, in which,
however, they did not assess the effects of preload alterations.
Relative independence of MVG from preload alterations as com-
pared to transmitral flow patterns was first reported by Shimizu et
al. (5) in 1998. In addition, I would like to emphasize that a robust
aspect of the tissue Doppler technique is the potential to assess
regional, rather than global, diastolic function noninvasively,
which should be validated and clinically applied in the near future.
Although the editorial comment by Dr. Shah raises an impor-
tant issue in the assessment of diastolic function and thus is very
informative, I am afraid his statement on the application of MVG
measurements for the assessment of diastolic function seems to be
inaccurate.
1724 Letters to the Editor JACC Vol. 43, No. 9, 2004
May 5, 2004:1723–5
Masaaki Uematsu, MD, PhD, FACC
Cardiovascular Division
Kansai Rosai Hospital
3-1-69 Inabaso
Amagasaki
Hyogo 660-8511
Japan
E-mail: uematsu@theia.ocn.ne.jp
doi:10.1016/j.jacc.2004.02.011
REFERENCES
1. Shah PM. Hypertrophic cardiomyopathy and diastolic dysfunction.
J Am Coll Cardiol 2003;42:286–7.
2. Kato T, Noda A, Izawa H, et al. Myocardial velocity gradient as a
noninvasively determined index of left ventricular diastolic dysfunction
in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol
2003;42:278–85.
3. Fleming AD, Xia X, McDicken WM, Sutherland GR, Fenn L.
Myocardial velocity gradients detected by Doppler imaging. Br J Radiol
1994;67:679–88.
4. Palka P, Lange A, Fleming AD, et al. Differences in myocardial velocity
gradient measured throughout the cardiac cycle in patients with hyper-
trophic cardiomyopathy, athletes and patients with left ventricular
hypertrophy due to hypertension. J Am Coll Cardiol 1997;30:760–8.
5. Shimizu Y, Uematsu M, Shimizu H, et al. Peak negative myocardial
velocity gradient in early diastole as a noninvasive indicator of left
ventricular diastolic function. J Am Coll Cardiol 1998;32:1418–25.
REPLY
I thank Dr. Masaaki Uematsu for his thoughts related to my
editorial comment dealing with hypertrophic cardiomyopathy and
diastolic function (1).
Fleming et al. (2) first described myocardial velocity gradients
detected by Doppler imaging and demonstrated Doppler velocity
gradient waveforms in systole as well as in diastole. They compared
these waveforms to rate of change of wall thickness both in systole
and diastole and reported cyclic consistency. They showed that
over 99% of systolic and 89% of early diastolic peaks in rate of
change of wall thickness occurred concurrently with a peak in
velocity gradient. Thus, their observations included Doppler ve-
locity gradients during systolic thickening and diastolic thinning of
the left ventricular posterior wall. They did not introduce this
method “merely for the evaluation of myocardial contractility” even
though they speculated on this potential.
As Dr. Uematsu, a second author on the contribution by
Shimizu et al. (3), points out, their study showed a relative
independence of Doppler myocardial velocity gradients to passive
leg raising, which altered transmitral flow velocity profile. How-
ever, they also reported that volume-reducing therapy in congestive
heart failure resulted in similar directional changes between veloc-
ity gradient and transmitral flow. This latter observation clearly
indicates influence of preload on both parameters.
Dr. Uematsu considers that a robust aspect of Doppler velocity
gradient is in assessment of regional rather than global diastolic
function. This optimism ignores a caution expressed by Fleming et
al. (2) that Doppler velocity gradient peaks may be influenced by
the angle of the ultrasound beam relative to the muscle fibers. An
oblique angle of the beam would yield a lower velocity gradient.
The ventricular wall is composed of both circular and oblique
fibers. This could have a profound effect on the noninvasive
measurements of myocardial velocity gradients. Thus, in addition
to physiologic and loading conditions mentioned in the editorial
comment (1), the myocardial structure in terms of fiber orientation
may add yet another confounding factor. We will do well to await
further studies in validation and clinical application of this intrigu-
ing new Doppler technique.
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